Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine

Inventors

FEDERICO, Maurizio Paolo Maria

Assignees

Istituto Superiors Di Sanita • Istituto Superiore di Sanità

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11559571-B2

Patent

Publication Date

2023-01-24

Expiration Date


Abstract

The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.

Core Innovation

The invention relates to a nucleic acid vaccine platform in which muscle cells are transfected with DNA encoding an exosome-anchoring fusion protein. The encoded fusion protein comprises human HIV-1 Nef protein with mutations 3C, 153L, and 177G fused at its C-terminus to an immunogenic antigen, so that engineered endogenous exosomes are generated.

The engineered endogenous exosomes are stated to cross-present antigen and induce antigen-specific CD8+ CTL responses in a subject. The platform is further described as producing CTL immune responses without detectable anti-antibody responses against the immunogenic antigen, and as breaking tolerance in a HER2/neu transgenic mouse model.

The approach supports broad selection of immunogenic antigens for CTL induction, including viral and tumor/tumor-associated antigens. It also includes experimental evidence of engineered exosome detection, cross-priming dependence on exosome biogenesis, CTL activity, and therapeutic effects including tumor growth inhibition or delay.

Claims Coverage

Independent claim clm-00001 covers inducing a therapeutically effective CTL immune response via intramuscular administration of a nucleic acid vaccine encoding a specific exosome-anchoring fusion protein. The claim contains 2 main inventive elements.

Nucleic acid vaccine encoding mutated Nef fusion to an immunogenic antigen

A nucleic acid expression vector comprising a polynucleotide encoding a fusion protein in which human HIV-1 Nef with mutations 3C, 153L and 177G is fused at its C-terminus to an immunogenic antigen.

Muscle administration to induce therapeutically effective CTL immune response

Administering the nucleic acid vaccine to the muscle of a subject, optionally with one or more pharmaceutically acceptable excipient and/or adjuvant, wherein the administration induces a therapeutically effective CTL immune response.

Overall, the independent claim is directed to muscle administration of a nucleic acid vaccine encoding a mutated human HIV-1 Nef (3C, 153L, 177G) exosome-anchoring fusion at the C-terminus to an immunogenic antigen, with the resulting induction of a therapeutically effective CTL immune response.

Stated Advantages

Induces antigen-specific CD8+ CTL responses.

Produces CTL immune responses without detectable anti-antibody responses against the immunogenic antigen.

Breaks tolerance in HER2/neu transgenic mice.

Inhibits or delays tumor growth.

Documented Applications

Inducing a therapeutically effective cytotoxic lymphocyte (CTL) immune response in a subject by administering a nucleic acid vaccine to the muscle.

Use of the method with a broad set of immunogenic antigens including viral antigens (e.g., HPV E6/E7, HIV antigens, Ebola antigens, West Nile NS3, HBV/HCV proteins, influenza NP/M1) and tumor/tumor-associated antigens (e.g., melanoma MAGE-A3/MART-1, Her2/neu, HoxB7).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.